James Callaway

FAQ About James Callaway

• What is James Callaway's address?

  James Callaway is located at
  San Diego, California, United States

• What is James Callaway's job title?

  James Callaway is a
  Dr. Callaway has over 30 years of biopharmaceutical leadership experience. Jim is currently CEO of KalGene, a development stage biotech company targeting Alzheimer's disease with sites in Montreal and San Diego. Previously he served as President and CEO of ArmaGen for several years transitioning the research company into a clinical stage company advancing antibody directed receptor-mediated transcytosis the delivery of biopharmaceuticals across the blood-brain barrier. He was previously President and CEO for Cebix Incorporated, where the team has been advancing a long-acting version of C-peptide as a potential therapeutic to treat and prevent the long-term complications of type 1 diabetes. Jim previously worked for 13 years at Athena Neurosciences (later Elan Pharmaceuticals) and was instrumental in the pharmaceutical development activities to support Tysabri. In addition, he led the program to develop Myobloc and secure approval of the BLA/PLA/MAA while serving as the lead accountable person in the design, construction, validation, and FDA approval of a biologics manufacturing plant. He also served as SVP, Program Executive for the Alzheimer’s Immunotherapy (bapineuzumab is the lead compound) program for nearly a decade, advancing it from IND filing to Phase 3 design. During his tenure at Elan, Jim was responsible for significant line function responsibilities including a worldwide Development organization of 200-plus scientists. Dr. Callaway also contributed to Bayer's world-wide approval for the first recombinant Factor VIII molecule to treat hemophilia A, SmithKline Beecham's (now GSK) research on recombinant flu and malaria vaccines as well as therapeutic proteins and antibodies, and also Ingene's (now Xoma) study of bactericidal peptides and collagenase X. Dr. Callaway received his Ph. D. in Biological Chemistry at UCLA while applying protein chemistry to the study of histone subunit interactions with in chromatin. Nuravax

• What industry does James Callaway currently work in?

  James Callaway currently works in the
  Nuravax

• What is James Callaway's area of expertise?

  James Callaway specializes in
  Dr. Callaway has over 30 years of biopharmaceutical leadership experience. Jim is currently CEO of KalGene, a development stage biotech company targeting Alzheimer's disease with sites in Montreal and San Diego. Previously he served as President and CEO of ArmaGen for several years transitioning the research company into a clinical stage company advancing antibody directed receptor-mediated transcytosis the delivery of biopharmaceuticals across the blood-brain barrier. He was previously President and CEO for Cebix Incorporated, where the team has been advancing a long-acting version of C-peptide as a potential therapeutic to treat and prevent the long-term complications of type 1 diabetes. Jim previously worked for 13 years at Athena Neurosciences (later Elan Pharmaceuticals) and was instrumental in the pharmaceutical development activities to support Tysabri. In addition, he led the program to develop Myobloc and secure approval of the BLA/PLA/MAA while serving as the lead accountable person in the design, construction, validation, and FDA approval of a biologics manufacturing plant. He also served as SVP, Program Executive for the Alzheimer’s Immunotherapy (bapineuzumab is the lead compound) program for nearly a decade, advancing it from IND filing to Phase 3 design. During his tenure at Elan, Jim was responsible for significant line function responsibilities including a worldwide Development organization of 200-plus scientists. Dr. Callaway also contributed to Bayer's world-wide approval for the first recombinant Factor VIII molecule to treat hemophilia A, SmithKline Beecham's (now GSK) research on recombinant flu and malaria vaccines as well as therapeutic proteins and antibodies, and also Ingene's (now Xoma) study of bactericidal peptides and collagenase X. Dr. Callaway received his Ph. D. in Biological Chemistry at UCLA while applying protein chemistry to the study of histone subunit interactions with in chromatin.

• Which languages does James Callaway speak? 

  James Callaway speaks the following languages:
  No languages available.

• Which industries has James Callaway previously worked in?   

  James Callaway has prior experience in the following industries:
  Kalgene Pharmaceuticals , Armagen , Cebix , Cebix , Elan Pharmaceuticals , Elan Pharmaceuticals , Bayer , Gsk , Xoma

• What is James Callaway’s work experience?  

  James Callaway has the following professional experience:
  Nuravax , Kalgene Pharmaceuticals , Callaway Innovations , Armagen , Cebix , Cebix , Elan Pharmaceuticals , Elan Pharmaceuticals , Bayer , Gsk , Xoma .

• How can I find James Callaway on LinkedIn?  

  You can view James Callaway’s
  LinkedIn profile at LinkedIn URL.

• What are James Callaway’s work email addresses?  

  James Callaway’s work email addresses are
  [email protected] .

• What company does James Callaway work for?  

  James Callaway works at
  Nuravax